Literature DB >> 28449521

Cancer of the esophagus and esophagogastric junction: an 8th edition staging primer.

Claire L Donohoe1, Alexander W Phillips1.   

Abstract

Year:  2017        PMID： 28449521      PMCID： PMC5394080          DOI： 10.21037/jtd.2017.03.39

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  17 in total

1.  Can CT-PET and Endoscopic Assessment Post-Neoadjuvant Chemoradiotherapy Predict Residual Disease in Esophageal Cancer?

Authors:  Helen M Heneghan; Claire Donohoe; Jessie Elliot; Zuhair Ahmed; Vinod Malik; Narayamasamy Ravi; John V Reynolds
Journal:  Ann Surg       Date:  2016-11       Impact factor: 12.969

2.  Clinical T2N0 Esophageal Cancer: Identifying Pretreatment Characteristics Associated With Pathologic Upstaging and the Potential Role for Induction Therapy.

Authors:  Pamela Samson; Varun Puri; Clifford Robinson; Craig Lockhart; Danielle Carpenter; Stephen Broderick; Daniel Kreisel; A Sasha Krupnick; G Alexander Patterson; Bryan Meyers; Traves Crabtree
Journal:  Ann Thorac Surg       Date:  2016-04-12       Impact factor: 4.330

3.  Cancer of the Esophagus and Esophagogastric Junction: An Eighth Edition Staging Primer.

Authors:  Thomas W Rice; Hemant Ishwaran; Mark K Ferguson; Eugene H Blackstone; Peter Goldstraw
Journal:  J Thorac Oncol       Date:  2016-10-31       Impact factor: 15.609

4.  Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.

Authors:  Christophe Mariette; Laetitia Dahan; Françoise Mornex; Emilie Maillard; Pascal-Alexandre Thomas; Bernard Meunier; Valérie Boige; Denis Pezet; William B Robb; Valérie Le Brun-Ly; Jean-François Bosset; Jean-Yves Mabrut; Jean-Pierre Triboulet; Laurent Bedenne; Jean-François Seitz
Journal:  J Clin Oncol       Date:  2014-06-30       Impact factor: 44.544

5.  Recommendations for clinical staging (cTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals.

Authors:  Thomas W Rice; Hemant Ishwaran; Eugene H Blackstone; Wayne L Hofstetter; David P Kelsen; Carolyn Apperson-Hansen
Journal:  Dis Esophagus       Date:  2016-11       Impact factor: 3.429

6.  A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.

Authors:  T N Walsh; N Noonan; D Hollywood; A Kelly; N Keeling; T P Hennessy
Journal:  N Engl J Med       Date:  1996-08-15       Impact factor: 91.245

7.  Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort.

Authors:  N K S Cheedella; A Suzuki; L Xiao; W L Hofstetter; D M Maru; T Taketa; K Sudo; M A Blum; S H Lin; J Welch; J H Lee; M S Bhutani; D C Rice; A A Vaporciyan; S G Swisher; J A Ajani
Journal:  Ann Oncol       Date:  2012-12-17       Impact factor: 32.976

8.  Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.

Authors:  Joel Tepper; Mark J Krasna; Donna Niedzwiecki; Donna Hollis; Carolyn E Reed; Richard Goldberg; Krystyna Kiel; Christopher Willett; David Sugarbaker; Robert Mayer
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

9.  Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol.

Authors:  Bo Jan Noordman; Joel Shapiro; Manon Cw Spaander; Kausilia K Krishnadath; Hanneke Wm van Laarhoven; Mark I van Berge Henegouwen; Grard Ap Nieuwenhuijzen; Richard van Hillegersberg; Meindert N Sosef; Ewout W Steyerberg; Bas Pl Wijnhoven; J Jan B van Lanschot
Journal:  JMIR Res Protoc       Date:  2015-06-29

10.  Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study.

Authors:  S R Markar; B J Noordman; H Mackenzie; J M Findlay; P R Boshier; M Ni; E W Steyerberg; A van der Gaast; M C C M Hulshof; N Maynard; M I van Berge Henegouwen; B P L Wijnhoven; J V Reynolds; J J B Van Lanschot; G B Hanna
Journal:  Ann Oncol       Date:  2017-03-01       Impact factor: 32.976
View more
  13 in total

1.  [Expressions of TAK1 and TAB1 in esophageal cancer and their correlation with prognosis].

Authors:  Sai Cao; Meirong Cheng; Sue Liu; Xiaole Duan; Mei Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-07-30

2.  Combining node location and node ratio as a prognostic factor for surgical resected non-small cell lung cancer: a population-based study.

Authors:  Huajie Xing; Mengyu Hu; Jingyu Chen; Yongqing Guo; Deruo Liu; Chaoyang Liang
Journal:  J Thorac Dis       Date:  2020-07       Impact factor: 2.895

3.  Prognostic implications and oncogenic roles of MYBL2 protein expression in esophageal squamous-cell carcinoma.

Authors:  Hui Qin; Yunyun Li; Hongyan Zhang; Feng Wang; Hongliu He; Xue Bai; Shanshan Li
Journal:  Onco Targets Ther       Date:  2019-03-08       Impact factor: 4.147

4.  Novel technique for lymphadenectomy along left recurrent laryngeal nerve during thoracoscopic esophagectomy.

Authors:  Wen-Shu Chen; Li-Huan Zhu; Wu-Jin Li; Peng-Jie Tu; Jian-Yuan Huang; Pei-Lin You; Xiao-Jie Pan
Journal:  World J Gastroenterol       Date:  2020-03-28       Impact factor: 5.742

5.  Prognostic Value of Combined Detection of Preoperative Albumin-to-Fibrinogen Ratio and Neutrophil-to-Lymphocyte Ratio in Operable Esophageal Squamous Cell Carcinoma Patients without Neoadjuvant Therapy.

Authors:  Zhiyuan Zheng; Donghong Lin; Qiaoqian Chen; Bin Zheng; Mingqiang Liang; Chun Chen; Wei Zheng
Journal:  Cancer Manag Res       Date:  2021-03-12       Impact factor: 3.989

6.  The role of vascular invasion and lymphatic invasion in predicting recurrent thoracic oesophageal squamous cell carcinoma.

Authors:  Yu Ma; Xi Yao; Zhenzhen Li; Jie Chen; Wensheng Li; Hongtao Wang; Lanjun Zhang; Jianfei Zhu
Journal:  World J Surg Oncol       Date:  2022-01-10       Impact factor: 2.754

7.  DAB2IP predicts treatment response and prognosis of ESCC patients and modulates its radiosensitivity through enhancing IR-induced activation of the ASK1-JNK pathway.

Authors:  Zhuting Tong; Weiyang Fang; Meng Xu; YeYe Xia; Rui Wang; Yue Li; Tianqi Zha; Liang Xiao; Shuhao Pan; Huiping Chai; Lei Zhao; Hao Wang; Huaguang Pan; Xiangcun Chen
Journal:  Cancer Cell Int       Date:  2022-03-05       Impact factor: 5.722

8.  Survival outcomes and prognostic factors of primary small cell carcinoma of the esophagus.

Authors:  Huikai Miao; Rongzhen Li; Dongni Chen; Jia Hu; Youfang Chen; Zhesheng Wen
Journal:  J Thorac Dis       Date:  2021-05       Impact factor: 2.895

9.  Significance of Neoadjuvant Downstaging in Carcinoma of Esophagus and Gastroesophageal Junction.

Authors:  S K Kamarajah; M Navidi; S Wahed; A Immanuel; N Hayes; S M Griffin; A W Phillips
Journal:  Ann Surg Oncol       Date:  2020-03-21       Impact factor: 5.344

10.  Transcervical inflatable mediastinoscopic esophagectomy versus thoracoscopic esophagectomy for local early- and intermediate-stage esophageal squamous cell carcinoma: A propensity score-matched analysis.

Authors:  Zihao Chen; Kenan Huang; Rongqiang Wei; Chengdong Liu; Yunhao Fang; Bin Wu; Zhifei Xu; Xinyu Ding; Hua Tang
Journal:  J Surg Oncol       Date:  2022-01-23       Impact factor: 2.885
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.